Public Market Listing
688331SSE
Live quotes, historical charts, and market capitalization for RemeGen Co., Ltd. are available on Yahoo Finance.
View quote & market cap on Yahoo Finance ↗External market data link · No third-party exchange redistribution
Assets
(6 total)
6Total Assets
0Approved
4Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | HER2Antibody–drug conjugate | Non-Small Cell Lung CancerBreast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 3 | PD-1 + VEGFMultispecific antibody | Non-Small Cell Lung Cancer | |
| Phase 3 | VEGF-A / FGF-2 (dual blockade)Protein / enzyme therapeutic | Age-Related Macular Degeneration | |
| Phase 3 | BAFF / APRILProtein / enzyme therapeutic | Systemic Lupus Erythematosus | |
| Phase 2 | METAntibody–drug conjugate | Non-Small Cell Lung Cancer | |
| Phase 1 | Undisclosed / early pipelineSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.